Knowledge Hub

Lung Transplant Rejection - Pipeline Review, H2 2016

Press release   •   Nov 30, 2016 04:48 EST has recently announced the addition of a market study “ Lung Transplant Rejection - Pipeline Review, H2 2016 ”, is a comparative analysis of the global market.

Lung Transplant Rejection - Pipeline Review, H2 2016


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection Pipeline Review, H2 2016, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 1, 4 and 1 respectively.Lung Transplant Rejection.

Download The sample Copy Of This Report:

Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


- The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).

- The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Content

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Lung Transplant Rejection Overview 6

Therapeutics Development 7

Pipeline Products for Lung Transplant Rejection - Overview 7

Lung Transplant Rejection - Therapeutics under Development by Companies 8

Lung Transplant Rejection - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Lung Transplant Rejection - Products under Development by Companies 12

Lung Transplant Rejection - Companies Involved in Therapeutics Development 13

Apeptico Forschung und Entwicklung GmbH 13

Dompe Farmaceutici S.p.A. 14

Kamada Ltd. 15

Novartis AG 16

Proteo, Inc. 17

Quark Pharmaceuticals, Inc. 18

Lung Transplant Rejection - Therapeutics Assessment 19

Assessment by Monotherapy Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

alpha-1 proteinase inhibitor (human) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

everolimus - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

FX-06 - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

QPI-1024 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

QPLI-1 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

R-554 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

R-801 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

reparixin - Drug Profile 52